纳米载体逆转肿瘤多药耐药机制的研究进展
|
摘要
肿瘤多药耐药(multidrug resistance,MDR)是导致肿瘤化疗失败、影响治疗效果的主要原因之一。随着生物技术的快速发展,纳米载体在逆转MDR方面呈现出增强药物靶向性、减少药物外排、降低药物毒副作用等明显优势,受到国内外学者的广泛关注。本文就肿瘤MDR发生机制和纳米载体逆转MDR方面的研究成果作一综述。
Multidrug resistance(MDR)is one of the main reasons to failure of tumor chemotherapy,and the influence on the treatment efficacy for cancer.With the rapid development of biotechnology,nanoparticle carrier has many advantages in MDR reversal,such as improving drug targeting to tumors,reducing drug efflux and lowering drug toxicity.Therefore,it has been caught scholars' eyes at home and abroad.This article will summarize the mechanism of tumor MDR and recent advances in the area of reversal effects of MDR by nanoparticle carrier.
Multidrug resistance(MDR)is one of the main reasons to failure of tumor chemotherapy,and the influence on the treatment efficacy for cancer.With the rapid development of biotechnology,nanoparticle carrier has many advantages in MDR reversal,such as improving drug targeting to tumors,reducing drug efflux and lowering drug toxicity.Therefore,it has been caught scholars' eyes at home and abroad.This article will summarize the mechanism of tumor MDR and recent advances in the area of reversal effects of MDR by nanoparticle carrier.
引文
[1]Palmeira A,Sousa E,Vasconcelos MH,et al.Three decades of P-gp inhibitors:skimming through several generations and scaffolds[J].Curr Med Chem,2012,19(13):1946-2025.
[2]Kathawala RJ,Gupta P,Ashby CR,et al.The modulation of ABC transporter-mediated multidrug resistance in cancer:A review of the past decade[J].Drug Resist Updates,2015,18(1):1-17.
[3]Wu Q,Yang Z,Nie Y,et al.Multi-drug resistance in cancer chemotherapeutics:Mechanisms and lab approaches[J].Cancer Lett,2014,347(2):159-166.
[4]Chiu C,Miller M C,Monahan R,et al.P-glycoprotein expression and amyloid accumulation in human aging and Alzheimer's disease:preliminary observations[J].Neurobiol Aging,2015,36(9):2475-2482.
[5]Massey PR,Fojo T,Bates SE.ABC Transporters:involvement in multidrug resistance and drug disposition[M].Handbook of Anticancer Pharmacokinetics and Pharmacodynamics.Springer New York,2014:373-400.
[6]芦金荣,王凤潇,李运曼,等.异黄酮衍生物的合成、肿瘤多药耐药逆转活性及2D-QSAR研究[J].中国药科大学学报,2013,44(4):296-302.
[7]浦龙健,刘浩,蒋琛琛.肿瘤多药耐药机制及逆转策略的研究进展[J].蚌埠医学院学报,2014,39(3):409-412.
[8]Korolnek T,Zhang J,Beardsley S,et al.Control of metazoan heme homeostasis by a conserved multidrug resistance protein[J].Cell Metab,2014,19(6):1008-1019.
[9]Ebert SP,Wetzel B,Myette RL,et al.Chalcogenopyrylium compounds as modulators of the ATP-binding cassette transporters P-glycoprotein(P-gp/ABCB1)and multidrug resistance protein 1(MRP1/ABCC1)[J].J Med Chem,2012,55(10):4683-4699.
[10]Durmus S,Sparidans RW,Esch AV,et al.Breast cancer resistance protein(BCRP/ABCG2)and P-glycoprotein(P-GP/ABCB1)restrict oral availability and brain accumulation of the PARP inhibitor rucaparib(AG-014699)[J].Pharmaceut Res,2015,32(1):37-46.
[11]Wood N,Streckfus CF.The expression of lung resistance protein in Saliva:a novel prognostic indicator protein for carcinoma of the breast[J].Cancer Invest,2015,33(10):510-515.
[12]Godlewska J,Luniewski W,Zagrodzki B,et al.Biological evaluation of omega-(dialkylamino)alkyl derivatives of 6H-indolo[2,3-b]quinoline-novel cytotoxic DNA topoisomeraseⅡinhibitors[J].Anticancer Res,2005,25(4):2857-2868.
[13]凌仕良,栾智宇,王海涛.肿瘤多药耐药机制及其中医药逆转的研究进展[J].湖南中医杂志,2014,30(12):157-158.
[14]Budillon A,Carbone C,di Gennaro E.Tissue transglutaminase:a new target to reverse cancer drug resistance[J].Amino acids,2013,44(1):63-72.
[15]Agnihotri N,Kumar S,Mehta K.Tissue transglutaminase as a central mediator in inflammation-induced progression of breast cancer[J].Breast Cancer Res,2013,15(1):1-9.
[16]Yakubov B,Chelladurai B,Schmitt J,et al.Extracellular tissue transglutaminase activates noncanonical NF-κB signaling and promotes metastasis in ovarian cancer[J].Neoplasia,2013,15(6):609-618.
[17]Bullenkamp J,G?ken J,Festy F,et al.Apoptin interacts with and regulates the activity of protein kinase C beta in cancer cells[J].Apoptosis,2015,20(6):831-842.
[18]Sharpe HJ,Pau G,Dijkgraaf GJ,et al.Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma[J].Cancer Cell,2015,27(3):327-341.
[19]揭惠,酉明巧,刘辉,等.肿瘤多药耐药的发生机制及逆转策略[J].中华中医药学刊,2013,31(7):216-220.
[20]Zhang Y,Chen H,Zhou S,et al.Sp1 and c-Myc modulate drug resistance of leukemia stem cells by regulating survivin expression through the ERK-MSK MAPK signaling pathway[J].Molec Cancer,2015,14(1):1-18.
[21]Salzano G,Navarro G,Trivedi MS,et al.Multifunctional polymeric micelles co-loaded with anti survivin siRNA and paclitaxel overcome drug resistance in an animal model of ovarian cancer[J].Molec Cancer Therap,2015,14(4):1075-1084.
[22]Schulze-Bergkamen H,Krammer PH.Apoptosis in cancer--implications for therapy[J].Semin Oncol,2004,31(1):90-119.
[23]Vinogradov S,Wei X.Cancer stem cells and drug resistance:the potential of nanomedicine[J].Nanomedicine,2012,7(4):597-615.
[24]Ellem SJ,De-Juan-Pardo EM,Risbridger GP.In vitro modeling of the prostate cancer microenvironment[J].Adv Drug Deliv rev,2014,79(1):214-221.
[25]胡振夏,符旭东.纳米载药系统逆转肿瘤多药耐药的研究进展[J].中国医院药学杂志,2011,31(20):1724-1727.
[26]赵晶晶,沈灵佳,周建平,等.纳米靶向给药系统载体材料的研究进展[J].药学进展,2015,39(3):161-169.
[27]Wolfbeis OS.An overview of nanoparticles commonly used in fluorescent bioimaging[J].Chem Soc Rev,2015,44(14):4743-4768.
[28]Zhao N,Cui HF.Advance of heparin-coated and heparin-based nanoparticles[J].Chin Pharm J,2013,48(18):6-7.
[29]Sun N,Zhu Y,Yuan L,et al.Nano-liposomes of entrapment lidocaine hydrochloride on in vitro permeability of narcotic[J].Pak J Pharm Sci,2015,28(1 Suppl):325-328.
[30]Uchida S,Kinoh H,Ishii T,et al.Systemic delivery of messenger RNA for the treatment of pancreatic cancer using polyplex nanomicelles with a cholesterol moiety[J].Biomaterials,2016,82(2):221-228.
[31]Hu CMJ,Zhang L.Nanoparticle-based combination therapy toward overcoming drug resistance in cancer[J].Biochem Pharmacol,2012,83(8):1104-1111.
[32]Zeinali SF,Majidi S,Nikzamir N,et al.Magnetic nanoparticles as potential candidates for biomedical and biological applications[J].Artif Cells Nanomed Biotechnol,2015,45(1):1-10.
[33]Jain V,Jain S,Mahajan SC.Nanomedicines based drug delivery systems for anti-cancer targeting and treatment[J].Curr Drug Deliv,2015,12(2):177-191.
[34]黄长文,蒋星星,殷香保,等.FTC-CD133纳米微粒抑制肝癌干细胞耐药性的研究[J].中国全科医学,2016,19(2):184-189.
[35]郑铁钢,郭全义,陈继营,等.载多柔比星磁性纳米颗粒逆转人骨肉瘤细胞多药耐药性的实验研究[J].肿瘤研究与临床,2015,27(6):361-364.
[36]宁婷,李月,徐翀.紫杉醇-汉防己甲素复合纳米粒的制备及其逆转MCF-7/ADR细胞多药耐药的研究[J].广东药学院学报,2015,31(5):566-570.
[37]Yhee JY,Song S,Lee SJ,et al.Cancer-targeted MDR-1 siRNA delivery using self-cross-linked glycol chitosan nanoparticles to overcome drug resistance[J].J Controll Rel,2015,198(28):1-9.
[38]Ren F,Chen R,Wang Y,et al.Paclitaxel-Loaded poly(n-butylcyanoacrylate)nanoparticle delivery system to overcome multidrug resistance in ovarian cancer[J].Pharm Res,2010:28(4):897-906.
[39]Ta T,Porter TM.Thermosensitive liposomes for localized delivery and triggered release of chemotherapy[J].J Controll Rel,2013,169(1):112-125.
[40]问天娇,高媛,陈喃喃,等.多药耐药1基因小干扰RNA阳离子脂质体逆转乳腺癌多药耐药的研究[J].中国药学杂志,2015,50(9):763-767.
[41]Zhou Y,Wang H,Zhu L.Overcoming the drug resistance in lung cancer cells with 4R22-modified paclitaxel liposome treatment[J].J Mol Diagn Ther,2016,8(1):17-22.
[42]周毅,王赫,朱丽娜.4R22修饰的紫杉醇脂质体对肺癌细胞多药耐药的逆转作用[J].分子诊断与治疗杂志,2016,8(1):17-22.
[43]Cosco D,Paolino D,Cilurzo F,et al.Gemcitabine and tamoxifen-loaded liposomes as multidrug carriers for the treatment of breast cancer diseases[J].Int J Pharm,2012,422(2):229-237.
[44]Wang K,Wu X,Wang J,et al.Cancer stem cell theory:therapeutic implications for nanomedicine[J].Int J Nanomed,2013,8(2):899-908.
[45]Apte A,Koren E,Koshkaryev A,et al.Doxorubicin in TAT peptide-modified multifunctional immunoliposomes demonstrates increased activity against both drug-sensitive and drugresistant ovarian cancer models[J].Cancer Biol Ther,2014,15(1):69-80.
[46]H?dicke A,Blume A.Interactions of Pluronic block copolymers with lipid monolayers studied by epi-fluorescence microscopy and by adsorption experiments[J].J Coll Int Sci,2013,407(10):327-338.
[47]Bajelan E,Haeri A,Vali AM,et al.Co-delivery of doxorubicin and PSC 833(Valspodar)by stealth nanoliposomes for efficient overcoming of multidrug resistance[J].J Pharm Pharmaceut Sci,2012,15(4):568-582.
[48]Han M,Lv Q,Tang XJ,et al.Overcoming drug resistance of MCF-7/ADR cells by altering intracellular distribution of doxorubicin via MVP knockdown with a novel siRNA polyamidoamine-hyaluronic acid complex[J].J Controll Rel,2012,163(2):136-144.
[49]Wang Y,Zhang Z,Sha X,et al.Reversal of paclitaxel-chemoresistance by mixed Pluronic P105/L101 micelles in human ovarian cancer SKOV-3/PTX cells[J].J Drug Deliv Sci Technol,2013,23(2):119-128.
[50]吴金花,段金虹,许海燕,等.载有槲皮素的PEG-PE胶束对乳腺癌细胞耐药性的逆转效应[J].基础医学与临床,2015,35(2):174-177.
[51]Fan Z,Chen C,Pang X,et al.Adding vitamin E-TPGS to the formulation of genexol-PM:specially mixed micelles improve drug-loading ability and cytotoxicity against multidrug-resistant tumors significantly[J].PLoS One,2015,10(4):e0120129.
[52]Wei T,Chen C,Liu J,et al.Anticancer drug nanomicelles formed by self-assembling amphiphilic dendrimer to combat cancer drug resistance[J].Proceed National Acad Sci,2015,112(10):2978-2983.
[52]Pritchard T,Rosengren RJ,Greish K,et al.Raloxifene nanomicelles reduce the growth of castrate-resistant prostate cancer[J].J Drug Targ,2016,24(5):441-449.
[53]Dong Y,Yang J,Liu H,et al.Site-specific drug-releasing polypeptide nanocarriers based on dual-pH response for enhanced therapeutic efficacy against drug-resistant tumors[J].Theranostics,2015,5(8):890-904.
[54]杨佳,程丽芳,程亮,等.依克立达双重敏感纳米递药系统的构建及其逆转多药耐药的考察[J].中国医药工业杂志,2016,47(3):288-293.
[55]Soma CE,Dubernet C,Bentolila D,et al.Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporine A in polyalkylcyanoacrylate nanoparticles[J].Biomaterials,2011,21(1):1-7.
[56]Zhao D,Liu N,Shi K,et al.Preparation of a multifunctional verapamil-loaded nano-carrier based on a self-assembling PEGylated prodrug.[J].Coll Surf B Biointerf,2015,(135):682-688.
[57]母发旭,唐洁,何勤.共载阿霉素和维拉帕米双修饰脂质体的制备及其对MCF-7/ADR细胞增殖的抑制作用[J].华西药学杂志,2015,30(4)∶396-399.
[58]黄菁,王玉珏,卢丽萍.纳米载体逆转肿瘤耐药的研究进展[J].实用药物与临床,2014,17(10):1337-1340.
[59]Binkhathlan Z,Lavasanifar A.P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer:current status and future perspectives[J].Curr Cancer Drug Targ,2013,13(3):326-346.
[60]Alfaro L,Hayes D,Boeneke C,et al.Physical properties of a frozen yogurt fortified with a nano-emulsion containing purple rice bran oil[J].LWT-Food Sci Technol,2015,62(2):1184-1191.
[2]Kathawala RJ,Gupta P,Ashby CR,et al.The modulation of ABC transporter-mediated multidrug resistance in cancer:A review of the past decade[J].Drug Resist Updates,2015,18(1):1-17.
[3]Wu Q,Yang Z,Nie Y,et al.Multi-drug resistance in cancer chemotherapeutics:Mechanisms and lab approaches[J].Cancer Lett,2014,347(2):159-166.
[4]Chiu C,Miller M C,Monahan R,et al.P-glycoprotein expression and amyloid accumulation in human aging and Alzheimer's disease:preliminary observations[J].Neurobiol Aging,2015,36(9):2475-2482.
[5]Massey PR,Fojo T,Bates SE.ABC Transporters:involvement in multidrug resistance and drug disposition[M].Handbook of Anticancer Pharmacokinetics and Pharmacodynamics.Springer New York,2014:373-400.
[6]芦金荣,王凤潇,李运曼,等.异黄酮衍生物的合成、肿瘤多药耐药逆转活性及2D-QSAR研究[J].中国药科大学学报,2013,44(4):296-302.
[7]浦龙健,刘浩,蒋琛琛.肿瘤多药耐药机制及逆转策略的研究进展[J].蚌埠医学院学报,2014,39(3):409-412.
[8]Korolnek T,Zhang J,Beardsley S,et al.Control of metazoan heme homeostasis by a conserved multidrug resistance protein[J].Cell Metab,2014,19(6):1008-1019.
[9]Ebert SP,Wetzel B,Myette RL,et al.Chalcogenopyrylium compounds as modulators of the ATP-binding cassette transporters P-glycoprotein(P-gp/ABCB1)and multidrug resistance protein 1(MRP1/ABCC1)[J].J Med Chem,2012,55(10):4683-4699.
[10]Durmus S,Sparidans RW,Esch AV,et al.Breast cancer resistance protein(BCRP/ABCG2)and P-glycoprotein(P-GP/ABCB1)restrict oral availability and brain accumulation of the PARP inhibitor rucaparib(AG-014699)[J].Pharmaceut Res,2015,32(1):37-46.
[11]Wood N,Streckfus CF.The expression of lung resistance protein in Saliva:a novel prognostic indicator protein for carcinoma of the breast[J].Cancer Invest,2015,33(10):510-515.
[12]Godlewska J,Luniewski W,Zagrodzki B,et al.Biological evaluation of omega-(dialkylamino)alkyl derivatives of 6H-indolo[2,3-b]quinoline-novel cytotoxic DNA topoisomeraseⅡinhibitors[J].Anticancer Res,2005,25(4):2857-2868.
[13]凌仕良,栾智宇,王海涛.肿瘤多药耐药机制及其中医药逆转的研究进展[J].湖南中医杂志,2014,30(12):157-158.
[14]Budillon A,Carbone C,di Gennaro E.Tissue transglutaminase:a new target to reverse cancer drug resistance[J].Amino acids,2013,44(1):63-72.
[15]Agnihotri N,Kumar S,Mehta K.Tissue transglutaminase as a central mediator in inflammation-induced progression of breast cancer[J].Breast Cancer Res,2013,15(1):1-9.
[16]Yakubov B,Chelladurai B,Schmitt J,et al.Extracellular tissue transglutaminase activates noncanonical NF-κB signaling and promotes metastasis in ovarian cancer[J].Neoplasia,2013,15(6):609-618.
[17]Bullenkamp J,G?ken J,Festy F,et al.Apoptin interacts with and regulates the activity of protein kinase C beta in cancer cells[J].Apoptosis,2015,20(6):831-842.
[18]Sharpe HJ,Pau G,Dijkgraaf GJ,et al.Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma[J].Cancer Cell,2015,27(3):327-341.
[19]揭惠,酉明巧,刘辉,等.肿瘤多药耐药的发生机制及逆转策略[J].中华中医药学刊,2013,31(7):216-220.
[20]Zhang Y,Chen H,Zhou S,et al.Sp1 and c-Myc modulate drug resistance of leukemia stem cells by regulating survivin expression through the ERK-MSK MAPK signaling pathway[J].Molec Cancer,2015,14(1):1-18.
[21]Salzano G,Navarro G,Trivedi MS,et al.Multifunctional polymeric micelles co-loaded with anti survivin siRNA and paclitaxel overcome drug resistance in an animal model of ovarian cancer[J].Molec Cancer Therap,2015,14(4):1075-1084.
[22]Schulze-Bergkamen H,Krammer PH.Apoptosis in cancer--implications for therapy[J].Semin Oncol,2004,31(1):90-119.
[23]Vinogradov S,Wei X.Cancer stem cells and drug resistance:the potential of nanomedicine[J].Nanomedicine,2012,7(4):597-615.
[24]Ellem SJ,De-Juan-Pardo EM,Risbridger GP.In vitro modeling of the prostate cancer microenvironment[J].Adv Drug Deliv rev,2014,79(1):214-221.
[25]胡振夏,符旭东.纳米载药系统逆转肿瘤多药耐药的研究进展[J].中国医院药学杂志,2011,31(20):1724-1727.
[26]赵晶晶,沈灵佳,周建平,等.纳米靶向给药系统载体材料的研究进展[J].药学进展,2015,39(3):161-169.
[27]Wolfbeis OS.An overview of nanoparticles commonly used in fluorescent bioimaging[J].Chem Soc Rev,2015,44(14):4743-4768.
[28]Zhao N,Cui HF.Advance of heparin-coated and heparin-based nanoparticles[J].Chin Pharm J,2013,48(18):6-7.
[29]Sun N,Zhu Y,Yuan L,et al.Nano-liposomes of entrapment lidocaine hydrochloride on in vitro permeability of narcotic[J].Pak J Pharm Sci,2015,28(1 Suppl):325-328.
[30]Uchida S,Kinoh H,Ishii T,et al.Systemic delivery of messenger RNA for the treatment of pancreatic cancer using polyplex nanomicelles with a cholesterol moiety[J].Biomaterials,2016,82(2):221-228.
[31]Hu CMJ,Zhang L.Nanoparticle-based combination therapy toward overcoming drug resistance in cancer[J].Biochem Pharmacol,2012,83(8):1104-1111.
[32]Zeinali SF,Majidi S,Nikzamir N,et al.Magnetic nanoparticles as potential candidates for biomedical and biological applications[J].Artif Cells Nanomed Biotechnol,2015,45(1):1-10.
[33]Jain V,Jain S,Mahajan SC.Nanomedicines based drug delivery systems for anti-cancer targeting and treatment[J].Curr Drug Deliv,2015,12(2):177-191.
[34]黄长文,蒋星星,殷香保,等.FTC-CD133纳米微粒抑制肝癌干细胞耐药性的研究[J].中国全科医学,2016,19(2):184-189.
[35]郑铁钢,郭全义,陈继营,等.载多柔比星磁性纳米颗粒逆转人骨肉瘤细胞多药耐药性的实验研究[J].肿瘤研究与临床,2015,27(6):361-364.
[36]宁婷,李月,徐翀.紫杉醇-汉防己甲素复合纳米粒的制备及其逆转MCF-7/ADR细胞多药耐药的研究[J].广东药学院学报,2015,31(5):566-570.
[37]Yhee JY,Song S,Lee SJ,et al.Cancer-targeted MDR-1 siRNA delivery using self-cross-linked glycol chitosan nanoparticles to overcome drug resistance[J].J Controll Rel,2015,198(28):1-9.
[38]Ren F,Chen R,Wang Y,et al.Paclitaxel-Loaded poly(n-butylcyanoacrylate)nanoparticle delivery system to overcome multidrug resistance in ovarian cancer[J].Pharm Res,2010:28(4):897-906.
[39]Ta T,Porter TM.Thermosensitive liposomes for localized delivery and triggered release of chemotherapy[J].J Controll Rel,2013,169(1):112-125.
[40]问天娇,高媛,陈喃喃,等.多药耐药1基因小干扰RNA阳离子脂质体逆转乳腺癌多药耐药的研究[J].中国药学杂志,2015,50(9):763-767.
[41]Zhou Y,Wang H,Zhu L.Overcoming the drug resistance in lung cancer cells with 4R22-modified paclitaxel liposome treatment[J].J Mol Diagn Ther,2016,8(1):17-22.
[42]周毅,王赫,朱丽娜.4R22修饰的紫杉醇脂质体对肺癌细胞多药耐药的逆转作用[J].分子诊断与治疗杂志,2016,8(1):17-22.
[43]Cosco D,Paolino D,Cilurzo F,et al.Gemcitabine and tamoxifen-loaded liposomes as multidrug carriers for the treatment of breast cancer diseases[J].Int J Pharm,2012,422(2):229-237.
[44]Wang K,Wu X,Wang J,et al.Cancer stem cell theory:therapeutic implications for nanomedicine[J].Int J Nanomed,2013,8(2):899-908.
[45]Apte A,Koren E,Koshkaryev A,et al.Doxorubicin in TAT peptide-modified multifunctional immunoliposomes demonstrates increased activity against both drug-sensitive and drugresistant ovarian cancer models[J].Cancer Biol Ther,2014,15(1):69-80.
[46]H?dicke A,Blume A.Interactions of Pluronic block copolymers with lipid monolayers studied by epi-fluorescence microscopy and by adsorption experiments[J].J Coll Int Sci,2013,407(10):327-338.
[47]Bajelan E,Haeri A,Vali AM,et al.Co-delivery of doxorubicin and PSC 833(Valspodar)by stealth nanoliposomes for efficient overcoming of multidrug resistance[J].J Pharm Pharmaceut Sci,2012,15(4):568-582.
[48]Han M,Lv Q,Tang XJ,et al.Overcoming drug resistance of MCF-7/ADR cells by altering intracellular distribution of doxorubicin via MVP knockdown with a novel siRNA polyamidoamine-hyaluronic acid complex[J].J Controll Rel,2012,163(2):136-144.
[49]Wang Y,Zhang Z,Sha X,et al.Reversal of paclitaxel-chemoresistance by mixed Pluronic P105/L101 micelles in human ovarian cancer SKOV-3/PTX cells[J].J Drug Deliv Sci Technol,2013,23(2):119-128.
[50]吴金花,段金虹,许海燕,等.载有槲皮素的PEG-PE胶束对乳腺癌细胞耐药性的逆转效应[J].基础医学与临床,2015,35(2):174-177.
[51]Fan Z,Chen C,Pang X,et al.Adding vitamin E-TPGS to the formulation of genexol-PM:specially mixed micelles improve drug-loading ability and cytotoxicity against multidrug-resistant tumors significantly[J].PLoS One,2015,10(4):e0120129.
[52]Wei T,Chen C,Liu J,et al.Anticancer drug nanomicelles formed by self-assembling amphiphilic dendrimer to combat cancer drug resistance[J].Proceed National Acad Sci,2015,112(10):2978-2983.
[52]Pritchard T,Rosengren RJ,Greish K,et al.Raloxifene nanomicelles reduce the growth of castrate-resistant prostate cancer[J].J Drug Targ,2016,24(5):441-449.
[53]Dong Y,Yang J,Liu H,et al.Site-specific drug-releasing polypeptide nanocarriers based on dual-pH response for enhanced therapeutic efficacy against drug-resistant tumors[J].Theranostics,2015,5(8):890-904.
[54]杨佳,程丽芳,程亮,等.依克立达双重敏感纳米递药系统的构建及其逆转多药耐药的考察[J].中国医药工业杂志,2016,47(3):288-293.
[55]Soma CE,Dubernet C,Bentolila D,et al.Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporine A in polyalkylcyanoacrylate nanoparticles[J].Biomaterials,2011,21(1):1-7.
[56]Zhao D,Liu N,Shi K,et al.Preparation of a multifunctional verapamil-loaded nano-carrier based on a self-assembling PEGylated prodrug.[J].Coll Surf B Biointerf,2015,(135):682-688.
[57]母发旭,唐洁,何勤.共载阿霉素和维拉帕米双修饰脂质体的制备及其对MCF-7/ADR细胞增殖的抑制作用[J].华西药学杂志,2015,30(4)∶396-399.
[58]黄菁,王玉珏,卢丽萍.纳米载体逆转肿瘤耐药的研究进展[J].实用药物与临床,2014,17(10):1337-1340.
[59]Binkhathlan Z,Lavasanifar A.P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer:current status and future perspectives[J].Curr Cancer Drug Targ,2013,13(3):326-346.
[60]Alfaro L,Hayes D,Boeneke C,et al.Physical properties of a frozen yogurt fortified with a nano-emulsion containing purple rice bran oil[J].LWT-Food Sci Technol,2015,62(2):1184-1191.